Welcome to our dedicated page for Neuropace news (Ticker: NPCE), a resource for investors and traders seeking the latest updates and insights on Neuropace stock.
NeuroPace Inc (NPCE) is a pioneering medical technology company developing brain-responsive neuromodulation systems for epilepsy treatment. This page serves as the definitive source for official company announcements, financial updates, and clinical progress reports.
Access timely updates on NPCE's innovative RNS System, including FDA regulatory milestones, partnership developments with leading epilepsy centers, and peer-reviewed clinical study results. Investors will find earnings reports and strategic initiatives, while healthcare professionals can track real-world treatment outcomes and technological refinements.
Our curated news collection features:
- Quarterly financial performance updates
- RNS System enhancement announcements
- Clinical trial data publications
- Regulatory clearance milestones
- Research collaborations with medical institutions
Bookmark this page for structured access to NPCE's evolving role in neurotechnology and epilepsy care innovation.
NeuroPace, Inc. (NPCE) reported total revenue of $18.1 million in Q1 2024, a 25% increase from Q1 2023. The company extended its term loan maturity, maintained full-year revenue guidance of $73 to $77 million, and achieved growth in RNS System and DIXI Medical sales. Operating expenses were managed effectively, resulting in decreased losses compared to the prior year. The company remains focused on expanding market reach and increasing access to RNS therapy for epilepsy patients.